Journal of Gynecologic Oncology (JGO)

This episode summarizes a cross-sectional study from Central China on HPV genotype distribution and infection risk factors. Ye Chen and colleagues found that HPV52, 16, and 58 were most common, with infection peaks in young and older women. High-risk factors included diabetes, anxiety, low work intensity, and multiple sexual partners. Condom use and HPV vaccination were protective. The study advoc...

In this episode of the JGO Podcast, we explore a recent study from Peking Union Medical College Hospital examining the role of adjuvant surgery in patients with high-risk chemorefractory or relapsed gestational choriocarcinoma who achieve complete remission following anti-PD-1 therapy. The retrospective analysis of 43 patients reveals no significant difference in survival outcomes between those wh...

This episode features an in-depth discussion of the Asian cohort analysis from the AtTEnd/ENGOT-EN7 phase III trial, which evaluated atezolizumab in combination with carboplatin and paclitaxel for advanced or recurrent endometrial carcinoma. While atezolizumab improved progression-free survival in mismatch repair-deficient tumors across both Asian and non-Asian populations, it showed no benefit—an...

In this episode, we review findings from the Japan subset of the DUO-E phase III trial, led by Shin Nishio and colleagues, which evaluated durvalumab with or without olaparib following chemotherapy in patients with newly diagnosed advanced or recurrent endometrial cancer. The study demonstrated a progression-free survival benefit in Japanese patients consistent with the global population, with a m...

In this episode, we discuss the final analysis of the KEYNOTE-826 subgroup study led by Dr. Yong-Man Kim, evaluating pembrolizumab plus chemotherapy with or without bevacizumab in East Asian patients with persistent, recurrent, or metastatic cervical cancer. The study demonstrated substantial improvements in progression-free and overall survival compared to placebo, with median progression-free su...

In this episode of the Journal of Gynecologic Oncology podcast, we review a recent meta-analysis by Tianyu Zhang and colleagues titled "Role of Adjuvant Chemotherapy in Stage IC Ovarian Granulosa Cell Tumors." The study analyzed data from 12 retrospective studies involving 695 patients to evaluate whether postoperative adjuvant chemotherapy offers any benefit over observation alone. The...

In this episode of the Journal of Gynecologic Oncology podcast, we discuss a study by Baldwin and colleagues titled Evaluation of the Role of Liver Metastasectomy in the Treatment of Stage IV Endometrial Cancer . Using data from the National Cancer Database, the researchers analyzed outcomes in 999 patients with metastatic endometrial cancer confined to the liver. The study found that patients who...

This episode explores a recent study on the increased risk of cardiovascular disease among adolescent and young adult survivors of cervical cancer. Using data from the Korean National Health Insurance Service, researchers found that these survivors face a 47% higher risk of cardiovascular disease compared to non-cancer controls, with those receiving chemoradiotherapy at particularly high risk for...

This episode discusses a multi-institutional study evaluating the impact of bevacizumab in frontline chemotherapy for advanced ovarian clear cell carcinoma. Researchers analyzed data from 178 patients treated between 2008 and 2018 and found that adding bevacizumab significantly improved progression-free and overall survival. Patients who received bevacizumab had a median progression-free survival...

In this episode of the Journal of Gynecologic Oncology podcast, we discuss a study by Kanno and colleagues examining the impact of cytoreductive surgery on outcomes in high tumor burden ovarian cancer following the introduction of poly ADP-ribose polymerase inhibitors. This retrospective analysis of 434 patients found that, while complete cytoreduction remains essential, the use of poly ADP-ribose...

This episode of the Journal of Gynecologic Oncology podcast explores a study by Berthet and colleagues on the role of platinum-free interval in predicting the benefit of second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma. Analyzing a retrospective cohort of 40 patients, the study found that patients with a progression-free survival of more than nine months had a significantly...

In this episode of the Journal of Gynecologic Oncology podcast, we discuss a systematic review and meta-analysis by Zhang and colleagues comparing carboplatin-based and cisplatin-based chemotherapy in the treatment of malignant gonadal germ cell tumors. The study, which analyzed data from eight studies involving 1,409 patients, found that while carboplatin was associated with a higher treatment fa...

This episode of the Journal of Gynecologic Oncology podcast explores a post hoc analysis of the Japanese Gynecologic Oncology Group 2043 study, led by Yosuke Konno in Japan. The study evaluated the prognostic significance of para-aortic lymphadenectomy and para-aortic lymph node metastasis in high-risk endometrial cancer. Findings showed that para-aortic lymphadenectomy did not independently impro...

In this episode of the Journal of Gynecologic Oncology Podcast, we discuss a recent study by Kristin Bixel and colleagues on the use of adjuvant hormone therapy in patients with early-stage low-grade endometrial stromal sarcoma. Using data from the National Cancer Database, the study analyzed over two thousand patients and found that while the use of hormonal therapy has increased over time, it do...

In this episode, we delve into a study titled “Functions, Interactions, and Prognostic Role of POLE: A Bioinformatics Analysis” by Carvajal-Veloza and colleagues, which explores the impact of POLE mutations in endometrial cancer. Using advanced bioinformatics tools, the researchers analyzed 30 mutations in the exonuclease domain of the POLE gene, highlighting their pathogenic effects on protein st...

In this episode of the JGO podcast, we delve into a cost-effectiveness analysis from the SHAPE trial, comparing simple hysterectomy to radical hysterectomy for patients with low-risk early-stage cervical cancer. The study, led by Dr. Janice S. Kwon and published in November 2024, found that simple hysterectomy was both more effective and less costly, with an average cost savings of 1,511 Canadian...

In this episode, we discuss a phase II study by Chen Li and colleagues that evaluates the efficacy and safety of toripalimab, a PD-1 inhibitor, combined with bevacizumab and platinum-based chemotherapy as a first-line treatment for refractory recurrent or metastatic cervical cancer. With an impressive objective response rate of 83.3% and a median progression-free survival of 22.6 months, the findi...

In this episode of the Journal of Gynecologic Oncology podcast, we discuss a study by Natsuki Osawa and colleagues titled "Oncological safety of minimally invasive surgery in borderline ovarian tumor and ovarian cancer: a retrospective comparative study." The research evaluates the outcomes of 45 patients who underwent laparoscopic surgery for presumed benign ovarian tumors, later diagnosed as bor...

In this episode, we review the multi-center study led by Zhong and colleagues, which investigates the efficacy of combining bevacizumab with chemotherapy in relapsed ovarian cancer after prior PARP inhibitor maintenance therapy. The study found that patients receiving the combination achieved a median progression-free survival of 11 months compared to 9 months with chemotherapy alone, with notable...

In this episode, we delve into the NIVEC study, a phase 2 trial investigating the use of nivolumab, a programmed cell death protein 1 inhibitor, as a neoadjuvant therapy for patients with mismatch repair deficient, surgically resectable endometrial cancer. The study explores whether this immunotherapy can improve complete response rates when combined with standard surgical and adjuvant treatments....

In this episode, we discuss an exciting study by Okazawa-Sakai and colleagues from Japan, titled "Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer." This research highlights how the gut bacterium Phascolarctobacterium is linked to improved progression-free survival in BRCA1/2-negative ovarian cancer patients receiving PARP inhibitors. We explore the implicatio...

This episode explores a study led by Dr. Shuai Huang from Beijing Hospital, examining the efficacy and safety of combining anlotinib, a multi-target tyrosine kinase inhibitor, with oral etoposide for treating platinum-resistant ovarian cancer. In a retrospective analysis of 22 patients, the combination therapy achieved a partial response rate of 45% and a disease control rate of 85%, with a median...

In this episode, we explore a new study on pembrolizumab’s effectiveness in microsatellite instability-high endometrial cancer, focusing on three subtypes: sporadic (MLH1 hypermethylated), Lynch-like syndrome, and Lynch syndrome-associated tumors. Findings suggest that patients with Lynch-like and Lynch syndrome tumors may experience higher response rates and longer survival with pembrolizumab, un...

In this episode, we introduce the REMPA trial, a study from the Japanese Gynecologic Oncology Group evaluating the safety and efficacy of Repeated Medroxyprogesterone Acetate therapy for young patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia who wish to preserve fertility. With recurrence rates remaining high after initial hormone therapy, the trial examin...

In this episode of the Journal of Gynecologic Oncology podcast, we discuss the findings from a recent study titled "Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial." The study evaluates the financial and clinical outcomes of simple versus radical hysterectomy for low-risk, early-stage cervic...